Corcept Therapeutics (CORT) Tops Q1 EPS by 3c, increases guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.71 --0%
Revenue Growth %: +12.1%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
JFIN, KEQU, LASE, More
Revenue Growth %: +12.1%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.25, $0.03 better than the analyst estimate of $0.22. Revenue for the quarter came in at $146.81 million versus the consensus estimate of $141.19 million.
GUIDANCE:
Corcept Therapeutics sees FY2024 revenue of $620-650 million, versus the consensus of $610.6 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Ennis (EBF) Reports In-Line Q1 EPS
- NVE Corporation names new CEO and expands board to seven members
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
